Halozyme Therapeutics, Inc. provided revenue guidance for the fiscal year 2023. For the period, the company expected total revenue of $815 million to $845 million, representing growth of greater than 20% over 2022 expected total revenue.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
52.4 USD | +0.65% |
|
+4.24% | +41.77% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+41.77% | 6.63B | |
+16.45% | 123B | |
+21.96% | 115B | |
+23.73% | 25.85B | |
-20.05% | 20.9B | |
-16.28% | 16.77B | |
-16.52% | 16.52B | |
-44.35% | 15.56B | |
+63.91% | 15.49B | |
+2.52% | 13.45B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Halozyme Therapeutics, Inc. Provides Revenue Guidance for the Fiscal Year 2023